Lpa confers increased CVD risk but treatment options unclear
NEW ORLEANS While multiple studies have shown that lipoproteina is associated with elevated risk for CVD treatments to reduce lipoproteina have not yet proven to reduce CVD risk an expert said at the...
View ArticleStatins often negatively interact with other CV drugs
NEW ORLEANS Many CV medications have interactions with statins so clinicians must understand the magnitude of these relationships to ensure no harm to their patients an expert said at the National...
View ArticleNew consensus document tackles nonstatin therapies for LDL reduction
In a new expert consensus statement the American College of Cardiology recommends trying lifestyle and statin therapies before nonstatin medical therapies in patients who require LDL lowering to manage...
View ArticlePCSK9 inhibitors benefit patients with residual LDL burden
NEW ORLEANS A leading authority on PCSK9 inhibitors told the audience at the National Lipid Association Scientific Sessions that while the drugs can lower LDL by large amounts use of PCSK9 inhibitors...
View ArticleCommunicating Statin Evidence to Support Shared Decisions
This essay highlights the principles of evidenceinformed shared decisionmaking in the context of statin guidelines but is widely applicable to other clinical decisions. BMC Family Practice
View ArticleMany statinnaive patients benefit from adding ezetimibe to statin therapy
NEW ORLEANS In patients recommended by guideline for statin therapy who had never before taken statins ezetimibe was often needed in addition to statins to achieve LDL goals according to an analysis...
View ArticlePharmaceutical industry payments may influence branded statin prescriptions
Physicians in Massachusetts who received payments from the pharmaceuticals industry had higher rates of prescribing branded statins compa
View ArticleEsperion Therapeutics Update
A Brief PreambleETC1002 bempedoic acid is an oral once daily small molecule that is being developed as a therapy for patients with elevated LDLC with a special focus on statin intolerance. Esperion is...
View ArticleAfter a heart attack people more likely to take statins as directed
Reuters Heath People may do a better job of following doctors' orders to take statin drugs prescribed to protect against cardiac problems after they wind up hospitalized for a heart attack a large...
View ArticleRegeneron Presents Positive Interim Data from Phase 2 ProofofConcept Study of...
TARRYTOWN N.Y. May 31 2016 PRNewswire &160;Regeneron Pharmaceuticals Inc. NASDAQ REGN today announced that positive preliminary results from an ongoing proofofconcept study of evinacumab REGN1500...
View ArticleDigitalization and Pharma Opportunity or Irrelevance
The pace of healthcare evolution and change is not slowing. This offers opportunities to pharma companies to positively support and ease the pain of transition and change and digital technology...
View ArticleCould statins prevent breast cancer returning
"Statins could be used in the treatment of breast cancer" Sky News report. Findings from a new study suggest the potential involvement of cholesterol in the recurrence of breast...
View ArticleVIDEO NLA ACC come to consensus on nonstatin therapy for CVD prevention
NEW ORLEANS In this video Carl E. Orringer MD FACC FNLA president of the National Lipid Association and associate professor of medicine at the University of Miami Miller School of Medicine discusses...
View ArticleVascepaR Icosapent Ethyl Data to Be Presented at American Diabetes...
BEDMINSTER NJ AND DUBLIN IRELANDMarketwired June 06 2016 ÂAmarin Corporation plcÂNASDAQ AMRNÂtoday announced that new data related to Vascepa icosapent ethyl will be presented at the upcoming American...
View ArticleStatins do not affect pneumonia patients LOS mortality
Statin therapy before and throughout hospitalization for communityacquired pneumonia did not appear to reduce hospital length of stay or inhospital mortality according to the results of a recent...
View ArticlePostrandomization Confounding in Randomized Clinical Trials
In this Viewpoint JoAnn Manson and colleagues discuss the risk of postrandomization confounding a bias that can be introduced in longduration trials of sustained interventions using statin initiation...
View ArticleInvestigational oral medication fails to meet trial endpoint does not lower...
Patients with hypercholesterolemia who received an oral investigational medication CAT2054 and statin therapy did not have a reduction in lowdensity lipoprotein LDL cholesterol which was the primary...
View ArticleVascepaR Icosapent Ethyl Showed Significant Reductions in Potentially...
BEDMINSTER NJ and DUBLIN IRELANDMarketwired June 11 2016 Amarin Corporation plc NASDAQ AMRN today announced additional data on Vascepa icosapent ethyl presented at the annual meeting of the American...
View ArticleU.S. and European Endocrinologists See a Continued Need for New Nonstatin...
BURLINGTON Mass. June 13 2016 PRNewswire &160;Decision Resources Group finds that despite the many therapies available there is an ongoing need for drugs that improve LDLC. Positive results from...
View Article